anti-CD22 CAR-T therapy

The median doses of CD22 and CD19 CAR T cell infusions were 4.1 × 10/kg and 4.0 × 10/kg, respectively. Both the estimated 1-year progression-free and overall survival rates were 55.6%. Our preliminary results indicated that salvage therapy with CD19/CD22 CAR T cell infusion alone and that in combination with ASCT are effective in treating some adult patients with r/r Burkitt lymphoma.

The high durable CR rates and favorable safety profiles supported the strong potential of the HDT-ASCT plus CD19/CD22 CAR-T cell cocktail therapy for the suboptimal group of R/R aggressive B-NHL who are less sensitive or failed to salvage chemotherapy. These early data were encouraging and informative to future trials to further test the efficacy and safety of the ASCT plus CAR-T therapy in a larger population.